ClinicalTrials.gg
CompletedNCT03257410Updated Jul 14, 2025Results posted

Theranova 400 Dialyzer In End Stage Renal Disease (ESRD) Patients

An interventional study of Theranova 400 dialyzer and Elisio-17H dialyzer in End Stage Renal Disease, sponsored by Vantive Health LLC. Completed at 20 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-14.

Sponsored by Vantive Health LLC (formerly part of Baxter Healthcare Corporation) · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
172
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 33 studies in Kidney Failure, Chronic by Baxter Healthcare Corporation — none open to participants now, none under way, none of them phase 3. Kidney Failure, Chronic · Baxter Healthcare Corporation.

Enrollment
6th of 29
172 · median 43
Started
2017
the only one that year
No phase
22 of 33
none open now
Registered
24th of 33
by date

Among the 33 studies in Kidney Failure, Chronic by Baxter Healthcare Corporation, this one is the 6th largest by enrollment of the 29 interventional ones that give a count, is the only one that started in 2017, is one of 22 with no phase, and was the 24th registered.

Kidney Failure, Chronic

2,114 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

None of the 33 studies in Kidney Failure, Chronic by Baxter Healthcare Corporation is open now. The open studies under Kidney Failure, Chronic, anywhere →

Who these studies take

Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 33 studies in Kidney Failure, Chronic by Baxter Healthcare Corporation as a file.
02

Study summary

The study evaluates the efficacy and safety of the Theranova 400 dialyzer compared with Elisio-17 H dialyzer in end stage renal disease patients receiving hemodialysis treatment. Efficacy will be determined by the removal of middle molecules (with different molecular size) from the blood compartment. Safety will be evaluated by maintaining pre-dialysis serum albumin levels and other safety events including laboratory tests and adverse events.

Patients will undergo 3 dialysis sessions per week, for 24 weeks.

03

Conditions studied

  • End Stage Renal Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ESRD patients age 22 and older, or between ages 18 and 21 with a weight ≥ 40kg.
  • Clinically stable as judged by the treating physician and as demonstrated by stable medical history for 30 days prior to enrollment, physical examination, and laboratory testing.
  • Hemodialysis therapy with high-flux dialyzers for at least 3 months immediately prior to study enrollment and expected to survive for the next 12 months.
  • Expected to maintain an acceptable urea clearance (Kt/V) with a dialyzer of an approximate surface area of 1.7 m2.
  • Currently being dialyzed at an in-center setting, on a schedule of 3 times per week.
  • Able to give after an explanation of the proposed study, and who are willing to comply with the study requirements for therapy during the entire study treatment period.
  • Have a stable functioning vascular access (arteriovenous fistula, graft, or dual lumen tunneled catheter); stable access will be confirmed by observed Kt/V >= 1.2 for past 2 measurements, and/or achievement of within 15% the prescribed blood flow rate over 3 treatments prior to study entry.

Exclusion criteria

Exclusion Criteria:

  • Are female and pregnant, lactating, or planning to become pregnant during the study period. Note: Female subjects of , defined as a woman \<55 years old who has not had a partial or full hysterectomy or oophorectomy, must have a negative serum beta human chorionic gonadotropin (β-hCG) pregnancy test at screening. Subjects of childbearing potential must use a medically acceptable means of during their participation in the study.
  • Have chronic liver disease.
  • Have a known paraprotein-associated disease.
  • Have known bleeding disorders (e.g., gastrointestinal bleed, colonic polyps, small bowel angiodysplasia, and active peptic ulcers).
  • Have had a major bleeding episode (i.e. soft tissue bleeding, blood in stool, prolonged nose bleeds, joint damage, retinal bleeding, extensive mucosal bleeding, exsanguination, cerebral hemorrhage) ≤ 12 weeks prior to randomization.
  • Have had a blood (red blood cell) transfusion ≤ 12 weeks prior to randomization.
  • Have had an acute infection ≤ 4 weeks prior to randomization.
  • Have active cancer, except for basal cell or squamous cell skin cancer.
  • Have a known serum κ/λ FLC ratio that is less than 0.37, or greater than 3.1.b
  • Have a known monoclonal gammopathy (monoclonal gammopathy of uncertain significance, smoldering [asymptomatic] multiple myeloma, symptomatic multiple myeloma, plasmacytomas, or plasma cell leukemia).
  • Have a known polyclonal gammopathy (connective tissue disease, liver disease, chronic infection, lymphoproliferative disorder, or other hematologic condition).
  • Have a positive serology test for or hepatitis infection.
  • Have a significant psychiatric disorder or mental disability.
  • Are scheduled for planned interventions requiring hospitalization > 1 week.
  • Are scheduled for living-donor transplantation within the study period + 3 months, plan to change to PD therapy within the next 9 months, plan to change to a home hemodialysis treatment, or plan to relocate to an area where no study center is located.
  • Are currently participating in another interventional clinical study or has participated in another interventional clinical study in the past 3 months.
  • Have a history of non-compliance with HD as assessed by an investigator.
  • Have had a major cardiovascular or cerebrovascular event within 3 months of study entry.
  • Have a history with consistent evidence of intradialytic hypotension.
  • Have uncontrolled (systolic BP > 180 mmHg) hypertension.
  • Have had adverse reactions to dialyzer materials.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
172 participants (actual)

Study arms

  • Experimental
    Theranova 400

    Three (3) dialysis sessions per week in an in-center setting over 24-week period.

    Device: Theranova 400 dialyzer

  • Active comparator
    Elisio-17H

    Three (3) dialysis sessions per week in an in-center setting over 24-week period.

    Device: Elisio-17H dialyzer

Interventions

  • DeviceTheranova 400 dialyzer

    Patients should continue with their pre-study hemodialysis prescriptions (in terms of treatment time, blood flow rate and dialysate flow rate) and prescriptions should be kept stable throughout the study.

    Also known as: MCO-Ci 400 Dialyzer, medium cut-off dialysis membrane

  • DeviceElisio-17H dialyzer

    Patients should continue with their pre-study hemodialysis prescriptions (in terms of treatment time, blood flow rate and dialysate flow rate) and prescriptions should be kept stable throughout the study.

06

What researchers measure

Primary outcomes

  1. Reduction Ratio of Lambda Immunoglobulin FLC at Week 24

    FLC=free light chains

    Time frame: Week 24

  2. Pre-dialysis Serum Level of Albumin at Week 24

    Time frame: Week 24

Secondary outcomes

  1. Reduction Ratio of Lambda Immunoglobulin FLC at Week 4 and Week 24

    FLC=free light chains

    Time frame: Week 4 and Week 24

  2. Reduction Ratio of Complement Factor D

    CFD=complement factor D

    Time frame: Week 4 and 24

  3. Reduction Ratio of κ FLC

    κ FLC = Kappa Free light chains

    Time frame: Week 4 and 24

  4. Reduction Ratio of Interleukin 6

    IL-6=interleukin 6

    Time frame: Week 4 and 24

  5. Reduction Ratio of Tumor Necrosis Factor Alpha

    TNFα=tumor necrosis factor alpha

    Time frame: Week 4 and 24

  6. Reduction Ratio of β2-microglobulin

    β2=beta 2

    Time frame: Week 4 and 24

  7. Change From Baseline in Pre-dialysis β2-microglobulin at Week 24

    Time frame: Baseline, Week 24

  8. Kt/Vurea

    Kt/Vurea = Dimensionless number used to quantify hemodialysis and peritoneal dialysis adequacy.

    Time frame: Week 4, 8, 12, 16, 20, 24

  9. Change From Baseline in Pre-dialysis Serum Albumin by Visit

    Time frame: Baseline, Week 4, 8, 12, 16, 20, 24

  10. Change From Baseline in Pre-dialysis Factor VII by Visit

    Time frame: Baseline, Week 12, Week 24

  11. Change From Baseline in Pre-dialysis Protein C by Visit

    Time frame: Baseline, Week 12, Week 24

  12. Change From Baseline in Pre-dialysis Vitamin A by Visit

    Time frame: Baseline, Week 4, Week 24

  13. nPNA (nPCR)

    nPNA=normalized Protein equivalent of Nitrogen Appearance, and nPCR=normalized Protein Catabolic Rate.

    Time frame: Week 4, 8, 12, 16, 20, 24

  14. Change From Baseline in Pre-dialysis Factor II by Visit

    Factor II (Prothrombin)

    Time frame: Baseline, Week 12, Week 24

  15. Change From Baseline in Sodium (mmol/L) at End of Study (up to Week 24)

    Time frame: Baseline and Week 24

  16. Change From Baseline in Potassium (mmol/L) at End of Study (up to Week 24)

    Time frame: Baseline and Week 24

  17. Change From Baseline in Calcium (mmol/L) at End of Study (up to Week 24)

    Time frame: Baseline, Week 24

  18. Change From Baseline in Phosphate (mmol/L) at End of Study (up to Week 24)

    Time frame: Baseline, Week 24

  19. Change From Baseline in Chloride (mmol/L) at End of Study (up to Week 24)

    Time frame: Baseline, Week 24

  20. Change From Baseline in Bicarbonate (mmol/L) at End of Study (up to Week 24)

    Time frame: Baseline, Week 24

  21. Change From Baseline in Glucose (mmol/L) at End of Study (up to Week 24)

    Time frame: Baseline, Week 24

  22. Change From Baseline in Prothrombin Time (Sec) at End of Study (up to Week 24)

    Time frame: Baseline, Week 24

  23. Change From Baseline in Prothrombin Intl. Normalized Ratio at End of Study (up to Week 24)

    Time frame: Baseline, Week 24

  24. Change From Baseline in Activated Partial Thromboplastin Time (Sec) at End of Study (up to Week 24)

    Time frame: Baseline, Week 24

  25. Change From Baseline in Hematocrit (L/L) at End of Study (up to Week 24)

    Time frame: Baseline, Week 24

  26. Change From Baseline in Hemoglobin (g/L) at End of Study (up to Week 24)

    Time frame: Baseline, Week 24

  27. Change From Baseline in Erythrocyte Mean Corpuscular Hemoglobin (pg) at End of Study (up to Week 24)

    Time frame: Baseline, Week 24

  28. Change From Baseline in Erythrocyte Mean Corpuscular HGB Concentration (g/L) at End of Study (up to Week 24)

    Time frame: Baseline, Week 24

  29. Change From Baseline in Erythrocyte Mean Corpuscular Volume (fL) at End of Study (up to Week 24)

    Time frame: Baseline, Week 24

  30. Change From Baseline in Platelets at End of Study (up to Week 24)

    Time frame: Baseline, Week 24

  31. Change From Baseline in Erythrocytes at End of Study (up to Week 24)

    Time frame: Baseline, Week 24

  32. Change From Baseline in Leukocytes at End of Study (up to Week 24)

    Time frame: Baseline, Week 24

  33. Change From Baseline in Basophils (%) at End of Study (up to Week 24)

    Time frame: Baseline, Week 24

  34. Change From Baseline in Eosinophils (%) at End of Study (up to Week 24)

    Time frame: Baseline, Week 24

  35. Change From Baseline in Lymphocytes (%) at End of Study (up to Week 24)

    Time frame: Baseline, Week 24

  36. Change From Baseline in Monocytes (%) at End of Study (up to Week 24)

    Time frame: Baseline, Week 24

  37. Change From Baseline in Neutrophils (%) at End of Study (up to Week 24)

    Time frame: Baseline, Week 24

  38. Change From Baseline in Pre-Dialysis Blood Urea Nitrogen (mmol Urea/L) at End of Study (up to Week 24)

    Time frame: Baseline, Week 24

  39. Change From Baseline in Post-Dialysis Blood Urea Nitrogen (mmol Urea/L) at End of Study (up to Week 24)

    Time frame: Baseline, Week 24

  40. Change From Baseline in BUN Reduction Ratio at End of Study (up to Week 24)

    Time frame: Baseline, Week 24

  41. Change From Baseline in Creatinine (μmol/L) at End of Study (up to Week 24)

    Time frame: Baseline, Week 24

  42. Kt/Vurea by Visit

    Time frame: Week 4, Week 8, Week 12, Week 16, Week 20, Week 24

  43. Change From Baseline in Vitamin A (μmol/L) at End of Study (up to Week 24)

    Time frame: Baseline, Week 24

  44. Change From Baseline in Cholesterol (mmol/L) at End of Study (up to Week 24)

    Time frame: Baseline, Week 24

  45. Change From Baseline in HDL Cholesterol (mmol/L) at End of Study (up to Week 24)

    Time frame: Baseline, Week 24

  46. Change From Baseline in LDL Cholesterol (mmol/L) at End of Study (up to Week 24)

    Time frame: Baseline, Week 24

  47. Change From Baseline in Triglycerides (mmol/L) at End of Study (up to Week 24)

    Time frame: Baseline, Week 24

  48. Change From Baseline in Alkaline Phosphatase (U/L) at End of Study (up to Week 24)

    Time frame: Baseline, Week 24

  49. Change From Baseline in Alanine Aminotransferase (U/L) at End of Study (up to Week 24)

    Time frame: Baseline, Week 24

  50. Change From Baseline in Aspartate Aminotransferase (U/L) at End of Study (up to Week 24)

    Time frame: Baseline, Week 24

  51. Change From Baseline in Direct Bilirubin (μmol/L) at End of Study (up to Week 24)

    Time frame: Baseline, Week 24

  52. Change From Baseline in Bilirubin (μmol/L) at End of Study (up to Week 24)

    Time frame: Baseline, Week 24

  53. Change From Baseline in Gamma Glutamyl Transferase (U/L) at End of Study (up to Week 24)

    Time frame: Baseline, Week 24

  54. Change From Baseline in Protein (g/L) at End of Study (up to Week 24)

    Time frame: Baseline, Week 24

  55. Change From Baseline in Globulin (g/L) at End of Study (up to Week 24)

    Time frame: Baseline, Week 24

  56. Change From Baseline in High-sensitivity C-reactive Protein (mg/L) at End of Study (up to Week 24)

    Time frame: Baseline, Week 24

  57. Change From Baseline in Prothrombin Activity (%) at End of Study (up to Week 24)

    Time frame: Baseline, Week 24

  58. Change From Baseline in Albumin (g/dL) at End of Study (up to Week 24)

    Time frame: Baseline, Week 24

  59. Change From Baseline in Factor XIV Activity (%) at End of Study (up to Week 24)

    Time frame: Baseline, Week 24

  60. Change From Baseline in Tumor Necrosis Factor (pg/mL) at End of Study (up to Week 24)

    Time frame: Baseline, Week 24

  61. Change From Baseline in Factor VII Activity (%) at End of Study (up to Week 24)

    Time frame: Baseline, Week 24

  62. Change From Baseline in Lambda Light Chain, Free (mg/L) at End of Study (up to Week 24)

    Time frame: Baseline, Week 24

  63. Change From Baseline in Interleukin 6 (pg/mL) at End of Study (up to Week 24)

    Time frame: Baseline, Week 24

  64. Change From Baseline in Complement Factor D (mcg/mL) at End of Study (up to Week 24)

    Time frame: Baseline, Week 24

  65. Change From Baseline in Kappa Light Chain, Free (mg/L) at End of Study (up to Week 24)

    Time frame: Baseline, Week 24

  66. Change From Baseline in Beta-2 Microglobulin (mg/L) at End of Study (up to Week 24)

    Time frame: Baseline, Week 24

07

Results

Posted Dec 19, 2020

Participant flow

Participant flow — Overall Study
MilestoneTheranova 400Elisio-17H
Started8686
Completed6565
Not completed2121
Withdrew: Adverse event23
Withdrew: Protocol violation12
Withdrew: Lost to follow-up10
Withdrew: Withdrawal by subject12
Withdrew: Physician decision11
Withdrew: Renal transplantation20
Withdrew: Switch to peritoneal dialysis10
Withdrew: Death32
Withdrew: Change to another dialysis center22
Withdrew: Missing 3 consecutive study treatments56
Withdrew: Miscellaneous22
Withdrew: Other01

Outcome measures

PrimaryReduction Ratio of Lambda Immunoglobulin FLC at Week 24

FLC=free light chains

Time frame:
Week 24
Reported as:
Mean · percentage ratio
Reduction Ratio of Lambda Immunoglobulin FLC at Week 24
percentage ratioTheranova 400Elisio-17H
Reduction Ratio of Lambda Immunoglobulin FLC at Week 2432.156 ± 12.60217.514 ± 12.7235
Statistical analysis
  • Theranova 400 vs Elisio-17H · Mean difference (final values): 14.828 · 95% CI 10.501 to 19.156Method=ANCOVA
PrimaryPre-dialysis Serum Level of Albumin at Week 24
Time frame:
Week 24
Reported as:
Mean · g/dL
Pre-dialysis Serum Level of Albumin at Week 24
g/dLTheranova 400Elisio-17H
Pre-dialysis Serum Level of Albumin at Week 244.030 ± 0.28434.018 ± 0.3935
Statistical analysis
  • Theranova 400 vs Elisio-17H · ANCOVA · Mean difference (final values): -0.015 · 95% CI -0.098 to 0.069
SecondaryReduction Ratio of Lambda Immunoglobulin FLC at Week 4 and Week 24

FLC=free light chains

Time frame:
Week 4 and Week 24
Reported as:
Mean · percentage ratio
Reduction Ratio of Lambda Immunoglobulin FLC at Week 4 and Week 24
percentage ratioTheranova 400Elisio-17H
Week 439.3 ± 14.48719.88 ± 11.394
Week 2433.29 ± 10.9617.19 ± 12.863
Statistical analysis
  • Theranova 400 vs Elisio-17H · Mixed-effect Model Repeated Measurement · p = <0.0001 · Mean difference (final values): 19.42
  • Theranova 400 vs Elisio-17H · Mixed-effect Model Repeated Measurement · p = <0.0001 · Mean difference (final values): 16.10
SecondaryReduction Ratio of Complement Factor D

CFD=complement factor D

Time frame:
Week 4 and 24
Reported as:
Mean · percentage ratio
Reduction Ratio of Complement Factor D
percentage ratioTheranova 400Elisio-17H
Week 436.78 ± 26.49911.71 ± 27.71
Week 2438.09 ± 11.23314.55 ± 11.298
Statistical analysis
  • Theranova 400 vs Elisio-17H · MMRM · p = <0.0001 · Mean difference (final values): 25.07
  • Theranova 400 vs Elisio-17H · MMRM · p = <0.0001 · Mean difference (final values): 23.54
SecondaryReduction Ratio of κ FLC

κ FLC = Kappa Free light chains

Time frame:
Week 4 and 24
Reported as:
Mean · percentage ratio
Reduction Ratio of κ FLC
percentage ratioTheranova 400Elisio-17H
Week 465.63 ± 18.56649.74 ± 15.111
Week 2459.27 ± 13.06843.91 ± 14.882
Statistical analysis
  • Theranova 400 vs Elisio-17H · MMRM · p = <0.0001 · Mean difference (final values): 15.89
  • Theranova 400 vs Elisio-17H · MMRM · p = <0.0001 · Mean difference (final values): 15.36
SecondaryReduction Ratio of Interleukin 6

IL-6=interleukin 6

Time frame:
Week 4 and 24
Reported as:
Mean · percentage ratio
Reduction Ratio of Interleukin 6
percentage ratioTheranova 400Elisio-17H
Week 4-4.62 ± 49.378-22.21 ± 69.618
Week 24-0.85 ± 46.214-14.83 ± 43.574
Statistical analysis
  • Theranova 400 vs Elisio-17H · MMRM · p = 0.0684 · Mean difference (final values): 17.59
  • Theranova 400 vs Elisio-17H · MMRM · p = 0.0806 · Mean difference (final values): 13.98
SecondaryReduction Ratio of Tumor Necrosis Factor Alpha

TNFα=tumor necrosis factor alpha

Time frame:
Week 4 and 24
Reported as:
Mean · percentage ratio
Reduction Ratio of Tumor Necrosis Factor Alpha
percentage ratioTheranova 400Elisio-17H
Week 447.29 ± 9.96637.9 ± 8.892
Week 2444.48 ± 10.21534.52 ± 10.673
SecondaryReduction Ratio of β2-microglobulin

β2=beta 2

Time frame:
Week 4 and 24
Reported as:
Mean · percentage ratio
Reduction Ratio of β2-microglobulin
percentage ratioTheranova 400Elisio-17H
Week 475.67 ± 8.264.86 ± 8.903
Week 2473.64 ± 10.42665.41 ± 9.428
SecondaryChange From Baseline in Pre-dialysis β2-microglobulin at Week 24
Time frame:
Baseline, Week 24
Reported as:
Mean · mg/L
Change From Baseline in Pre-dialysis β2-microglobulin at Week 24
mg/LTheranova 400Elisio-17H
Change From Baseline in Pre-dialysis β2-microglobulin at Week 24-3.95 ± 5.614-1.16 ± 6.128
SecondaryKt/Vurea

Kt/Vurea = Dimensionless number used to quantify hemodialysis and peritoneal dialysis adequacy.

Time frame:
Week 4, 8, 12, 16, 20, 24
Reported as:
Mean · Kt/Vurea
Kt/Vurea
Kt/VureaTheranova 400Elisio-17H
Week 41.58 ± 0.2661.58 ± 0.427
Week 81.62 ± 0.2881.51 ± 0.316
Week 121.58 ± 0.2941.55 ± 0.328
Week 161.56 ± 0.2681.59 ± 0.48
Week 201.57 ± 0.2971.55 ± 0.371
Week 241.51 ± 0.311.54 ± 0.467
SecondaryChange From Baseline in Pre-dialysis Serum Albumin by Visit
Time frame:
Baseline, Week 4, 8, 12, 16, 20, 24
Reported as:
Mean · g/dL
Change From Baseline in Pre-dialysis Serum Albumin by Visit
g/dLTheranova 400Elisio-17H
Week 4-0.08 ± 0.2440 ± 0.203
Week 8-0.11 ± 0.2540.00 ± 0.216
Week 12-0.12 ± 0.289-0.04 ± 0.229
Week 16-0.13 ± 0.335-0.03 ± 0.315
Week 20-0.08 ± 0.2790.02 ± 0.258
Week 240.01 ± 0.2500.04 ± 0.256
Statistical analysis
  • Theranova 400 vs Elisio-17H · Mixed-effect Model Repeated Measurement · p = 0.0347 · Mean difference (final values): -0.07
  • Theranova 400 vs Elisio-17H · Mixed-effect Model Repeated Measurement · p = 0.0036 · Mean difference (final values): -0.10
  • Theranova 400 vs Elisio-17H · Mixed-effect Model Repeated Measurement · p = 0.129 · Mean difference (final values): -0.06
  • Theranova 400 vs Elisio-17H · Mixed-effect Model Repeated Measurement · p = 0.1149 · Mean difference (final values): -0.08
  • Theranova 400 vs Elisio-17H · Mixed-effect Model Repeated Measurement · p = 0.0688 · Mean difference (final values): -0.08
  • Theranova 400 vs Elisio-17H · Mixed-effect Model Repeated Measurement · p = 0.6097 · Mean difference (final values): -0.02
SecondaryChange From Baseline in Pre-dialysis Factor VII by Visit
Time frame:
Baseline, Week 12, Week 24
Reported as:
Mean · percentage activity
Change From Baseline in Pre-dialysis Factor VII by Visit
percentage activityTheranova 400Elisio-17H
Week 123.59 ± 24.0577.79 ± 27.798
Week 240.38 ± 34.5729.19 ± 48.575
Statistical analysis
  • Theranova 400 vs Elisio-17H · Mixed-effect Model Repeated Measurement · p = 0.1472 · Mean difference (final values): -6.32
  • Theranova 400 vs Elisio-17H · Mixed-effect Model Repeated Measurement · p = 0.1207 · Mean difference (final values): -11.18
SecondaryChange From Baseline in Pre-dialysis Protein C by Visit
Time frame:
Baseline, Week 12, Week 24
Reported as:
Mean · percentage activity
Change From Baseline in Pre-dialysis Protein C by Visit
percentage activityTheranova 400Elisio-17H
Week 121.12 ± 15.7111.76 ± 16.378
Week 240.14 ± 19.376-1.78 ± 18.781
Statistical analysis
  • Theranova 400 vs Elisio-17H · Mixed-effect Model Repeated Measurement · p = 0.9775 · Mean difference (final values): -0.07
  • Theranova 400 vs Elisio-17H · Mixed-effect Model Repeated Measurement · p = 0.5538 · Mean difference (final values): 1.72
SecondaryChange From Baseline in Pre-dialysis Vitamin A by Visit
Time frame:
Baseline, Week 4, Week 24
Reported as:
Mean · μmol/L
Change From Baseline in Pre-dialysis Vitamin A by Visit
μmol/LTheranova 400Elisio-17H
Week 4-0.29 ± 0.983-0.04 ± 0.939
Week 24-0.33 ± 0.832-0.15 ± 1.096
Statistical analysis
  • Theranova 400 vs Elisio-17H · Mixed-effect Model Repeated Measurement · p = 0.1100 · Mean difference (final values): -0.23
  • Theranova 400 vs Elisio-17H · Mixed-effect Model Repeated Measurement · p = 0.4607 · Mean difference (final values): -0.11
SecondarynPNA (nPCR)

nPNA=normalized Protein equivalent of Nitrogen Appearance, and nPCR=normalized Protein Catabolic Rate.

Time frame:
Week 4, 8, 12, 16, 20, 24
Reported as:
Mean · g/kg/d
nPNA (nPCR)
g/kg/dTheranova 400Elisio-17H
Week 40.983 ± 0.24731.056 ± 0.3088
Week 81.013 ± 0.23801.023 ± 0.2936
Week 120.971 ± 0.25731.030 ± 0.2664
Week 161.022 ± 0.28690.971 ± 0.2881
Week 200.988 ± 0.26661.024 ± 0.3366
Week 240.947 ± 0.24501.012 ± 0.2891
Statistical analysis
  • Theranova 400 vs Elisio-17H · Mixed-effect Model Repeated Measurement · p = 0.0791 · Mean difference (final values): -0.0787
  • Theranova 400 vs Elisio-17H · Mixed-effect Model Repeated Measurement · p = 0.9505 · Mean difference (final values): -0.0027
  • Theranova 400 vs Elisio-17H · Mixed-effect Model Repeated Measurement · p = 0.1521 · Mean difference (final values): -0.0615
  • Theranova 400 vs Elisio-17H · Mixed-effect Model Repeated Measurement · p = 0.2489 · Mean difference (final values): 0.0538
  • Theranova 400 vs Elisio-17H · Mixed-effect Model Repeated Measurement · p = 0.4936 · Mean difference (final values): -0.0345
  • Theranova 400 vs Elisio-17H · Mixed-effect Model Repeated Measurement · p = 0.1497 · Mean difference (final values): -0.0663
SecondaryChange From Baseline in Pre-dialysis Factor II by Visit

Factor II (Prothrombin)

Time frame:
Baseline, Week 12, Week 24
Reported as:
Mean · percent activity
Change From Baseline in Pre-dialysis Factor II by Visit
percent activityTheranova 400Elisio-17H
Week 123.45 ± 11.5073.19 ± 13.284
Week 243.85 ± 11.6785.78 ± 15.394
Statistical analysis
  • Theranova 400 vs Elisio-17H · Mixed-effect Model Repeated Measurement · p = 0.9001 · Mean difference (final values): -0.25
  • Theranova 400 vs Elisio-17H · Mixed-effect Model Repeated Measurement · p = 0.3279 · Mean difference (final values): -2.33
SecondaryChange From Baseline in Sodium (mmol/L) at End of Study (up to Week 24)
Time frame:
Baseline and Week 24
Reported as:
Mean · mmol/L
Change From Baseline in Sodium (mmol/L) at End of Study (up to Week 24)
mmol/LTheranova 400Elisio-17H
Change From Baseline in Sodium (mmol/L) at End of Study (up to Week 24)-0.20 ± 3.1920.00 ± 3.671
Statistical analysis
  • Theranova 400 vs Elisio-17H · ANCOVA · p = 0.6576 · Mean difference (final values): 0.20
SecondaryChange From Baseline in Potassium (mmol/L) at End of Study (up to Week 24)
Time frame:
Baseline and Week 24
Reported as:
Mean · mmol/L
Change From Baseline in Potassium (mmol/L) at End of Study (up to Week 24)
mmol/LTheranova 400Elisio-17H
Change From Baseline in Potassium (mmol/L) at End of Study (up to Week 24)0.08 ± 0.727-0.23 ± 0.665
Statistical analysis
  • Theranova 400 vs Elisio-17H · ANCOVA · p = 0.0058 · Mean difference (final values): 0.29
SecondaryChange From Baseline in Calcium (mmol/L) at End of Study (up to Week 24)
Time frame:
Baseline, Week 24
Reported as:
Mean · mmol/L
Change From Baseline in Calcium (mmol/L) at End of Study (up to Week 24)
mmol/LTheranova 400Elisio-17H
Change From Baseline in Calcium (mmol/L) at End of Study (up to Week 24)-0.06 ± 0.154-0.02 ± 0.151
Statistical analysis
  • Theranova 400 vs Elisio-17H · ANCOVA · p = 0.034 · Mean difference (final values): -0.05
SecondaryChange From Baseline in Phosphate (mmol/L) at End of Study (up to Week 24)
Time frame:
Baseline, Week 24
Reported as:
Mean · mmol/L
Change From Baseline in Phosphate (mmol/L) at End of Study (up to Week 24)
mmol/LTheranova 400Elisio-17H
Change From Baseline in Phosphate (mmol/L) at End of Study (up to Week 24)-0.03 ± 0.438-0.19 ± 0.500
Statistical analysis
  • Theranova 400 vs Elisio-17H · ANCOVA · p = 0.0285 · Mean difference (final values): 0.16
SecondaryChange From Baseline in Chloride (mmol/L) at End of Study (up to Week 24)
Time frame:
Baseline, Week 24
Reported as:
Mean · mmol/L
Change From Baseline in Chloride (mmol/L) at End of Study (up to Week 24)
mmol/LTheranova 400Elisio-17H
Change From Baseline in Chloride (mmol/L) at End of Study (up to Week 24)0.09 ± 3.4880.43 ± 4.108
Statistical analysis
  • Theranova 400 vs Elisio-17H · ANCOVA · p = 0.9069 · Mean difference (final values): -0.06
SecondaryChange From Baseline in Bicarbonate (mmol/L) at End of Study (up to Week 24)
Time frame:
Baseline, Week 24
Reported as:
Mean · mmol/L
Change From Baseline in Bicarbonate (mmol/L) at End of Study (up to Week 24)
mmol/LTheranova 400Elisio-17H
Change From Baseline in Bicarbonate (mmol/L) at End of Study (up to Week 24)1.31 ± 3.0531.37 ± 3.080
Statistical analysis
  • Theranova 400 vs Elisio-17H · ANCOVA · p = 0.8413 · Mean difference (final values): 0.09
SecondaryChange From Baseline in Glucose (mmol/L) at End of Study (up to Week 24)
Time frame:
Baseline, Week 24
Reported as:
Mean · mmol/L
Change From Baseline in Glucose (mmol/L) at End of Study (up to Week 24)
mmol/LTheranova 400Elisio-17H
Change From Baseline in Glucose (mmol/L) at End of Study (up to Week 24)-0.20 ± 2.1970.47 ± 2.858
Statistical analysis
  • Theranova 400 vs Elisio-17H · ANCOVA · p = 0.0125 · Mean difference (final values): -0.97
SecondaryChange From Baseline in Prothrombin Time (Sec) at End of Study (up to Week 24)
Time frame:
Baseline, Week 24
Reported as:
Mean · Sec
Change From Baseline in Prothrombin Time (Sec) at End of Study (up to Week 24)
SecTheranova 400Elisio-17H
Change From Baseline in Prothrombin Time (Sec) at End of Study (up to Week 24)-0.04 ± 4.016-0.49 ± 6.305
Statistical analysis
  • Theranova 400 vs Elisio-17H · ANCOVA · p = 0.6891 · Mean difference (final values): 0.22
SecondaryChange From Baseline in Prothrombin Intl. Normalized Ratio at End of Study (up to Week 24)
Time frame:
Baseline, Week 24
Reported as:
Mean · ratio
Change From Baseline in Prothrombin Intl. Normalized Ratio at End of Study (up to Week 24)
ratioTheranova 400Elisio-17H
Change From Baseline in Prothrombin Intl. Normalized Ratio at End of Study (up to Week 24)-0.01 ± 0.341-0.05 ± 0.527
Statistical analysis
  • Theranova 400 vs Elisio-17H · ANCOVA · p = 0.6043 · Mean difference (final values): 0.02
SecondaryChange From Baseline in Activated Partial Thromboplastin Time (Sec) at End of Study (up to Week 24)
Time frame:
Baseline, Week 24
Reported as:
Mean · Sec
Change From Baseline in Activated Partial Thromboplastin Time (Sec) at End of Study (up to Week 24)
SecTheranova 400Elisio-17H
Change From Baseline in Activated Partial Thromboplastin Time (Sec) at End of Study (up to Week 24)-0.82 ± 16.682-0.96 ± 15.424
Statistical analysis
  • Theranova 400 vs Elisio-17H · ANCOVA · p = 0.5067 · Mean difference (final values): 1.39
SecondaryChange From Baseline in Hematocrit (L/L) at End of Study (up to Week 24)
Time frame:
Baseline, Week 24
Reported as:
Mean · L/L
Change From Baseline in Hematocrit (L/L) at End of Study (up to Week 24)
L/LTheranova 400Elisio-17H
Change From Baseline in Hematocrit (L/L) at End of Study (up to Week 24)0.03 ± 0.0550.01 ± 0.042
Statistical analysis
  • Theranova 400 vs Elisio-17H · ANCOVA · p = 0.0297 · Mean difference (net): 0.02
SecondaryChange From Baseline in Hemoglobin (g/L) at End of Study (up to Week 24)
Time frame:
Baseline, Week 24
Reported as:
Mean · g/L
Change From Baseline in Hemoglobin (g/L) at End of Study (up to Week 24)
g/LTheranova 400Elisio-17H
Change From Baseline in Hemoglobin (g/L) at End of Study (up to Week 24)2.74 ± 15.569-0.11 ± 11.221
Statistical analysis
  • Theranova 400 vs Elisio-17H · ANCOVA · p = 0.1325 · Mean difference (final values): 3.24
SecondaryChange From Baseline in Erythrocyte Mean Corpuscular Hemoglobin (pg) at End of Study (up to Week 24)
Time frame:
Baseline, Week 24
Reported as:
Mean · pg
Change From Baseline in Erythrocyte Mean Corpuscular Hemoglobin (pg) at End of Study (up to Week 24)
pgTheranova 400Elisio-17H
Change From Baseline in Erythrocyte Mean Corpuscular Hemoglobin (pg) at End of Study (up to Week 24)-0.12 ± 1.079-0.35 ± 1.153
Statistical analysis
  • Theranova 400 vs Elisio-17H · ANCOVA · p = 0.2304 · Mean difference (final values): 0.22
SecondaryChange From Baseline in Erythrocyte Mean Corpuscular HGB Concentration (g/L) at End of Study (up to Week 24)
Time frame:
Baseline, Week 24
Reported as:
Mean · g/L
Change From Baseline in Erythrocyte Mean Corpuscular HGB Concentration (g/L) at End of Study (up to Week 24)
g/LTheranova 400Elisio-17H
Change From Baseline in Erythrocyte Mean Corpuscular HGB Concentration (g/L) at End of Study (up to Week 24)-18.54 ± 16.053-15.12 ± 21.075
Statistical analysis
  • Theranova 400 vs Elisio-17H · ANCOVA · p = 0.5785 · Mean difference (final values): -1.59
SecondaryChange From Baseline in Erythrocyte Mean Corpuscular Volume (fL) at End of Study (up to Week 24)
Time frame:
Baseline, Week 24
Reported as:
Mean · fL
Change From Baseline in Erythrocyte Mean Corpuscular Volume (fL) at End of Study (up to Week 24)
fLTheranova 400Elisio-17H
Change From Baseline in Erythrocyte Mean Corpuscular Volume (fL) at End of Study (up to Week 24)4.88 ± 5.3711.93 ± 4.778
Statistical analysis
  • Theranova 400 vs Elisio-17H · ANCOVA · p = 0.0067 · Mean difference (final values): 2.55
SecondaryChange From Baseline in Platelets at End of Study (up to Week 24)
Time frame:
Baseline, Week 24
Reported as:
Mean · 10^9 cells/L
Change From Baseline in Platelets at End of Study (up to Week 24)
10^9 cells/LTheranova 400Elisio-17H
Change From Baseline in Platelets at End of Study (up to Week 24)-8.65 ± 41.7117.99 ± 49.215
Statistical analysis
  • Theranova 400 vs Elisio-17H · ANCOVA · p = 0.0434 · Mean difference (final values): -14.93
SecondaryChange From Baseline in Erythrocytes at End of Study (up to Week 24)
Time frame:
Baseline, Week 24
Reported as:
Mean · 10^12 cells/L
Change From Baseline in Erythrocytes at End of Study (up to Week 24)
10^12 cells/LTheranova 400Elisio-17H
Change From Baseline in Erythrocytes at End of Study (up to Week 24)0.10 ± 0.4820.04 ± 0.365
Statistical analysis
  • Theranova 400 vs Elisio-17H · ANCOVA · p = 0.3281 · Mean difference (final values): 0.07
SecondaryChange From Baseline in Leukocytes at End of Study (up to Week 24)
Time frame:
Baseline, Week 24
Reported as:
Mean · 10^9 cells/L
Change From Baseline in Leukocytes at End of Study (up to Week 24)
10^9 cells/LTheranova 400Elisio-17H
Change From Baseline in Leukocytes at End of Study (up to Week 24)-0.22 ± 1.6400.49 ± 2.464
Statistical analysis
  • Theranova 400 vs Elisio-17H · ANCOVA · p = 0.0463 · Mean difference (final values): -0.67
SecondaryChange From Baseline in Basophils (%) at End of Study (up to Week 24)
Time frame:
Baseline, Week 24
Reported as:
Mean · % of total white blood count (WBC)
Change From Baseline in Basophils (%) at End of Study (up to Week 24)
% of total white blood count (WBC)Theranova 400Elisio-17H
Change From Baseline in Basophils (%) at End of Study (up to Week 24)0.05 ± 0.369-0.02 ± 0.408
Statistical analysis
  • Theranova 400 vs Elisio-17H · ANCOVA · p = 0.1925 · Mean difference (final values): 0.08
SecondaryChange From Baseline in Eosinophils (%) at End of Study (up to Week 24)
Time frame:
Baseline, Week 24
Reported as:
Mean · % of total WBC
Change From Baseline in Eosinophils (%) at End of Study (up to Week 24)
% of total WBCTheranova 400Elisio-17H
Change From Baseline in Eosinophils (%) at End of Study (up to Week 24)0.17 ± 3.259-0.29 ± 2.397
Statistical analysis
  • Theranova 400 vs Elisio-17H · ANCOVA · p = 0.2569 · Mean difference (final values): 0.44
SecondaryChange From Baseline in Lymphocytes (%) at End of Study (up to Week 24)
Time frame:
Baseline, Week 24
Reported as:
Mean · % of total WBC
Change From Baseline in Lymphocytes (%) at End of Study (up to Week 24)
% of total WBCTheranova 400Elisio-17H
Change From Baseline in Lymphocytes (%) at End of Study (up to Week 24)0.14 ± 6.979-0.69 ± 8.052
Statistical analysis
  • Theranova 400 vs Elisio-17H · ANCOVA · p = 0.5709 · Mean difference (final values): 0.63
SecondaryChange From Baseline in Monocytes (%) at End of Study (up to Week 24)
Time frame:
Baseline, Week 24
Reported as:
Mean · % of total WBC
Change From Baseline in Monocytes (%) at End of Study (up to Week 24)
% of total WBCTheranova 400Elisio-17H
Change From Baseline in Monocytes (%) at End of Study (up to Week 24)-0.49 ± 2.261-1.07 ± 3.479
Statistical analysis
  • Theranova 400 vs Elisio-17H · ANCOVA · p = 0.217 · Mean difference (final values): 0.51
SecondaryChange From Baseline in Neutrophils (%) at End of Study (up to Week 24)
Time frame:
Baseline, Week 24
Reported as:
Mean · % of total WBC
Change From Baseline in Neutrophils (%) at End of Study (up to Week 24)
% of total WBCTheranova 400Elisio-17H
Change From Baseline in Neutrophils (%) at End of Study (up to Week 24)0.16 ± 8.7441.98 ± 9.485
Statistical analysis
  • Theranova 400 vs Elisio-17H · ANCOVA · p = 0.2386 · Mean difference (final values): -1.53
SecondaryChange From Baseline in Pre-Dialysis Blood Urea Nitrogen (mmol Urea/L) at End of Study (up to Week 24)
Time frame:
Baseline, Week 24
Reported as:
Mean · mmol urea/L
Change From Baseline in Pre-Dialysis Blood Urea Nitrogen (mmol Urea/L) at End of Study (up to Week 24)
mmol urea/LTheranova 400Elisio-17H
Change From Baseline in Pre-Dialysis Blood Urea Nitrogen (mmol Urea/L) at End of Study (up to Week 24)-1.82 ± 5.299-0.69 ± 4.784
Statistical analysis
  • Theranova 400 vs Elisio-17H · ANCOVA · p = 0.1769 · Mean difference (final values): -1.14
SecondaryChange From Baseline in Post-Dialysis Blood Urea Nitrogen (mmol Urea/L) at End of Study (up to Week 24)
Time frame:
Baseline, Week 24
Reported as:
Mean · mmol urea/L
Change From Baseline in Post-Dialysis Blood Urea Nitrogen (mmol Urea/L) at End of Study (up to Week 24)
mmol urea/LTheranova 400Elisio-17H
Change From Baseline in Post-Dialysis Blood Urea Nitrogen (mmol Urea/L) at End of Study (up to Week 24)-0.53 ± 2.360-0.57 ± 2.066
Statistical analysis
  • Theranova 400 vs Elisio-17H · ANCOVA · p = 0.8102 · Mean difference (final values): -0.09
SecondaryChange From Baseline in BUN Reduction Ratio at End of Study (up to Week 24)
Time frame:
Baseline, Week 24
Reported as:
Mean · no unit
Change From Baseline in BUN Reduction Ratio at End of Study (up to Week 24)
no unitTheranova 400Elisio-17H
Change From Baseline in BUN Reduction Ratio at End of Study (up to Week 24)0.33 ± 9.2980.68 ± 8.963
Statistical analysis
  • Theranova 400 vs Elisio-17H · ANCOVA · p = 0.9672 · Mean difference (final values): -0.06
SecondaryChange From Baseline in Creatinine (μmol/L) at End of Study (up to Week 24)
Time frame:
Baseline, Week 24
Reported as:
Mean · μmol/L
Change From Baseline in Creatinine (μmol/L) at End of Study (up to Week 24)
μmol/LTheranova 400Elisio-17H
Change From Baseline in Creatinine (μmol/L) at End of Study (up to Week 24)-17.45 ± 160.343-36.44 ± 153.168
Statistical analysis
  • Theranova 400 vs Elisio-17H · ANCOVA · p = 0.2697 · Mean difference (final values): 27.34
SecondaryKt/Vurea by Visit
Time frame:
Week 4, Week 8, Week 12, Week 16, Week 20, Week 24
Reported as:
Mean · no unit
Kt/Vurea by Visit
no unitTheranova 400Elisio-17H
Week 41.58 ± 0.2661.58 ± 0.427
Week 81.62 ± 0.2881.51 ± 0.316
Week 121.58 ± 0.2941.55 ± 0.328
Week 161.56 ± 0.2681.59 ± 0.480
Week 201.57 ± 0.2971.55 ± 0.371
Week 241.51 ± 0.3101.54 ± 0.467
SecondaryChange From Baseline in Vitamin A (μmol/L) at End of Study (up to Week 24)
Time frame:
Baseline, Week 24
Reported as:
Mean · μmol/L
Change From Baseline in Vitamin A (μmol/L) at End of Study (up to Week 24)
μmol/LTheranova 400Elisio-17H
Change From Baseline in Vitamin A (μmol/L) at End of Study (up to Week 24)-0.35 ± 0.826-0.01 ± 0.899
SecondaryChange From Baseline in Cholesterol (mmol/L) at End of Study (up to Week 24)
Time frame:
Baseline, Week 24
Reported as:
Mean · mmol/L
Change From Baseline in Cholesterol (mmol/L) at End of Study (up to Week 24)
mmol/LTheranova 400Elisio-17H
Change From Baseline in Cholesterol (mmol/L) at End of Study (up to Week 24)-0.19 ± 0.766-0.24 ± 0.705
Statistical analysis
  • Theranova 400 vs Elisio-17H · ANCOVA · p = 0.7189 · Mean difference (final values): 0.04
SecondaryChange From Baseline in HDL Cholesterol (mmol/L) at End of Study (up to Week 24)
Time frame:
Baseline, Week 24
Reported as:
Mean · mmol/L
Change From Baseline in HDL Cholesterol (mmol/L) at End of Study (up to Week 24)
mmol/LTheranova 400Elisio-17H
Change From Baseline in HDL Cholesterol (mmol/L) at End of Study (up to Week 24)0.04 ± 0.266-0.03 ± 0.276
Statistical analysis
  • Theranova 400 vs Elisio-17H · ANCOVA · p = 0.097 · Mean difference (final values): 0.07
SecondaryChange From Baseline in LDL Cholesterol (mmol/L) at End of Study (up to Week 24)
Time frame:
Baseline, Week 24
Reported as:
Mean · mmol/L
Change From Baseline in LDL Cholesterol (mmol/L) at End of Study (up to Week 24)
mmol/LTheranova 400Elisio-17H
Change From Baseline in LDL Cholesterol (mmol/L) at End of Study (up to Week 24)-0.07 ± 0.663-0.18 ± 0.807
Statistical analysis
  • Theranova 400 vs Elisio-17H · ANCOVA · p = 0.4513 · Mean difference (final values): 0.09
SecondaryChange From Baseline in Triglycerides (mmol/L) at End of Study (up to Week 24)
Time frame:
Baseline, Week 24
Reported as:
Mean · mmol/L
Change From Baseline in Triglycerides (mmol/L) at End of Study (up to Week 24)
mmol/LTheranova 400Elisio-17H
Change From Baseline in Triglycerides (mmol/L) at End of Study (up to Week 24)-0.15 ± 0.661-0.02 ± 0.672
Statistical analysis
  • Theranova 400 vs Elisio-17H · ANCOVA · p = 0.0733 · Mean difference (final values): -0.18
SecondaryChange From Baseline in Alkaline Phosphatase (U/L) at End of Study (up to Week 24)
Time frame:
Baseline, Week 24
Reported as:
Mean · U/L
Change From Baseline in Alkaline Phosphatase (U/L) at End of Study (up to Week 24)
U/LTheranova 400Elisio-17H
Change From Baseline in Alkaline Phosphatase (U/L) at End of Study (up to Week 24)-1.97 ± 37.7832.19 ± 32.725
Statistical analysis
  • Theranova 400 vs Elisio-17H · ANCOVA · p = 0.5326 · Mean difference (final values): -3.42
SecondaryChange From Baseline in Alanine Aminotransferase (U/L) at End of Study (up to Week 24)
Time frame:
Baseline, Week 24
Reported as:
Mean · U/L
Change From Baseline in Alanine Aminotransferase (U/L) at End of Study (up to Week 24)
U/LTheranova 400Elisio-17H
Change From Baseline in Alanine Aminotransferase (U/L) at End of Study (up to Week 24)-2.17 ± 8.168-0.51 ± 8.018
Statistical analysis
  • Theranova 400 vs Elisio-17H · ANCOVA · p = 0.3042 · Mean difference (final values): -1.11
SecondaryChange From Baseline in Aspartate Aminotransferase (U/L) at End of Study (up to Week 24)
Time frame:
Baseline, Week 24
Reported as:
Mean · U/L
Change From Baseline in Aspartate Aminotransferase (U/L) at End of Study (up to Week 24)
U/LTheranova 400Elisio-17H
Change From Baseline in Aspartate Aminotransferase (U/L) at End of Study (up to Week 24)-0.75 ± 6.816-0.01 ± 5.870
Statistical analysis
  • Theranova 400 vs Elisio-17H · ANCOVA · p = 0.5534 · Mean difference (final values): -0.58
SecondaryChange From Baseline in Direct Bilirubin (μmol/L) at End of Study (up to Week 24)
Time frame:
Baseline, Week 24
Reported as:
Mean · μmol/L
Change From Baseline in Direct Bilirubin (μmol/L) at End of Study (up to Week 24)
μmol/LTheranova 400Elisio-17H
Change From Baseline in Direct Bilirubin (μmol/L) at End of Study (up to Week 24)1.53 ± 2.6030.23 ± 1.107
Statistical analysis
  • Theranova 400 vs Elisio-17H · ANCOVA · p = 0.2958 · Mean difference (final values): 1.34
SecondaryChange From Baseline in Bilirubin (μmol/L) at End of Study (up to Week 24)
Time frame:
Baseline, Week 24
Reported as:
Mean · μmol/L
Change From Baseline in Bilirubin (μmol/L) at End of Study (up to Week 24)
μmol/LTheranova 400Elisio-17H
Change From Baseline in Bilirubin (μmol/L) at End of Study (up to Week 24)-1.06 ± 2.960-0.66 ± 2.040
Statistical analysis
  • Theranova 400 vs Elisio-17H · ANCOVA · p = 0.0998 · Mean difference (final values): -0.63
SecondaryChange From Baseline in Gamma Glutamyl Transferase (U/L) at End of Study (up to Week 24)
Time frame:
Baseline, Week 24
Reported as:
Mean · U/L
Change From Baseline in Gamma Glutamyl Transferase (U/L) at End of Study (up to Week 24)
U/LTheranova 400Elisio-17H
Change From Baseline in Gamma Glutamyl Transferase (U/L) at End of Study (up to Week 24)-0.66 ± 22.587-1.68 ± 21.724
Statistical analysis
  • Theranova 400 vs Elisio-17H · ANCOVA · p = 0.9952 · Mean difference (final values): 0.02
SecondaryChange From Baseline in Protein (g/L) at End of Study (up to Week 24)
Time frame:
Baseline, Week 24
Reported as:
Mean · g/L
Change From Baseline in Protein (g/L) at End of Study (up to Week 24)
g/LTheranova 400Elisio-17H
Change From Baseline in Protein (g/L) at End of Study (up to Week 24)-1.55 ± 4.576-0.95 ± 4.223
Statistical analysis
  • Theranova 400 vs Elisio-17H · ANCOVA · p = 0.3063 · Mean difference (final values): -0.71
SecondaryChange From Baseline in Globulin (g/L) at End of Study (up to Week 24)
Time frame:
Baseline, Week 24
Reported as:
Mean · g/L
Change From Baseline in Globulin (g/L) at End of Study (up to Week 24)
g/LTheranova 400Elisio-17H
Change From Baseline in Globulin (g/L) at End of Study (up to Week 24)-2.07 ± 3.635-1.27 ± 3.216
Statistical analysis
  • Theranova 400 vs Elisio-17H · ANCOVA · p = 0.1098 · Mean difference (final values): -0.85
SecondaryChange From Baseline in High-sensitivity C-reactive Protein (mg/L) at End of Study (up to Week 24)
Time frame:
Baseline, Week 24
Reported as:
Mean · mg/L
Change From Baseline in High-sensitivity C-reactive Protein (mg/L) at End of Study (up to Week 24)
mg/LTheranova 400Elisio-17H
Change From Baseline in High-sensitivity C-reactive Protein (mg/L) at End of Study (up to Week 24)-0.96 ± 4.168-0.40 ± 4.600
Statistical analysis
  • Theranova 400 vs Elisio-17H · ANCOVA · p = 0.0766 · Mean difference (final values): -1.44
SecondaryChange From Baseline in Prothrombin Activity (%) at End of Study (up to Week 24)
Time frame:
Baseline, Week 24
Reported as:
Mean · percentage activity
Change From Baseline in Prothrombin Activity (%) at End of Study (up to Week 24)
percentage activityTheranova 400Elisio-17H
Change From Baseline in Prothrombin Activity (%) at End of Study (up to Week 24)3.85 ± 11.6785.78 ± 15.394
Statistical analysis
  • Theranova 400 vs Elisio-17H · ANCOVA · p = 0.2886 · Mean difference (final values): -2.58
SecondaryChange From Baseline in Albumin (g/dL) at End of Study (up to Week 24)
Time frame:
Baseline, Week 24
Reported as:
Mean · g/dL
Change From Baseline in Albumin (g/dL) at End of Study (up to Week 24)
g/dLTheranova 400Elisio-17H
Change From Baseline in Albumin (g/dL) at End of Study (up to Week 24)0.01 ± 0.2500.04 ± 0.256
Statistical analysis
  • Theranova 400 vs Elisio-17H · ANCOVA · p = 0.4513 · Mean difference (final values): -0.03
SecondaryChange From Baseline in Factor XIV Activity (%) at End of Study (up to Week 24)
Time frame:
Baseline, Week 24
Reported as:
Mean · percentage activity
Change From Baseline in Factor XIV Activity (%) at End of Study (up to Week 24)
percentage activityTheranova 400Elisio-17H
Change From Baseline in Factor XIV Activity (%) at End of Study (up to Week 24)0.14 ± 19.376-1.78 ± 18.781
Statistical analysis
  • Theranova 400 vs Elisio-17H · ANCOVA · p = 0.5992 · Mean difference (final values): 1.56
SecondaryChange From Baseline in Tumor Necrosis Factor (pg/mL) at End of Study (up to Week 24)
Time frame:
Baseline, Week 24
Reported as:
Mean · pg/mL
Change From Baseline in Tumor Necrosis Factor (pg/mL) at End of Study (up to Week 24)
pg/mLTheranova 400Elisio-17H
Change From Baseline in Tumor Necrosis Factor (pg/mL) at End of Study (up to Week 24)-0.47 ± 1.9990.08 ± 1.645
Statistical analysis
  • Theranova 400 vs Elisio-17H · ANCOVA · p = 0.3836 · Mean difference (final values): -0.26
SecondaryChange From Baseline in Factor VII Activity (%) at End of Study (up to Week 24)
Time frame:
Baseline, Week 24
Reported as:
Mean · percentage activity
Change From Baseline in Factor VII Activity (%) at End of Study (up to Week 24)
percentage activityTheranova 400Elisio-17H
Change From Baseline in Factor VII Activity (%) at End of Study (up to Week 24)0.38 ± 34.5729.19 ± 48.575
Statistical analysis
  • Theranova 400 vs Elisio-17H · ANCOVA · p = 0.0769 · Mean difference (final values): -13.07
SecondaryChange From Baseline in Lambda Light Chain, Free (mg/L) at End of Study (up to Week 24)
Time frame:
Baseline, Week 24
Reported as:
Mean · mg/L
Change From Baseline in Lambda Light Chain, Free (mg/L) at End of Study (up to Week 24)
mg/LTheranova 400Elisio-17H
Change From Baseline in Lambda Light Chain, Free (mg/L) at End of Study (up to Week 24)-19.40 ± 31.6351.75 ± 29.946
Statistical analysis
  • Theranova 400 vs Elisio-17H · ANCOVA · p = 0.0002 · Mean difference (final values): -19.56
SecondaryChange From Baseline in Interleukin 6 (pg/mL) at End of Study (up to Week 24)
Time frame:
Baseline, Week 24
Reported as:
Mean · pg/mL
Change From Baseline in Interleukin 6 (pg/mL) at End of Study (up to Week 24)
pg/mLTheranova 400Elisio-17H
Change From Baseline in Interleukin 6 (pg/mL) at End of Study (up to Week 24)0.20 ± 5.4491.64 ± 6.473
Statistical analysis
  • Theranova 400 vs Elisio-17H · ANCOVA · p = 0.1825 · Mean difference (final values): -1.39
SecondaryChange From Baseline in Complement Factor D (mcg/mL) at End of Study (up to Week 24)
Time frame:
Baseline, Week 24
Reported as:
Mean · mcg/mL
Change From Baseline in Complement Factor D (mcg/mL) at End of Study (up to Week 24)
mcg/mLTheranova 400Elisio-17H
Change From Baseline in Complement Factor D (mcg/mL) at End of Study (up to Week 24)0.13 ± 4.7421.89 ± 4.838
Statistical analysis
  • Theranova 400 vs Elisio-17H · ANCOVA · p = 0.0957 · Mean difference (final values): -1.24
SecondaryChange From Baseline in Kappa Light Chain, Free (mg/L) at End of Study (up to Week 24)
Time frame:
Baseline, Week 24
Reported as:
Mean · mg/L
Change From Baseline in Kappa Light Chain, Free (mg/L) at End of Study (up to Week 24)
mg/LTheranova 400Elisio-17H
Change From Baseline in Kappa Light Chain, Free (mg/L) at End of Study (up to Week 24)-84.81 ± 97.359-43.01 ± 75.677
Statistical analysis
  • Theranova 400 vs Elisio-17H · ANCOVA · p = 0.0012 · Mean difference (final values): -34.02
SecondaryChange From Baseline in Beta-2 Microglobulin (mg/L) at End of Study (up to Week 24)
Time frame:
Baseline, Week 24
Reported as:
Mean · mg/L
Change From Baseline in Beta-2 Microglobulin (mg/L) at End of Study (up to Week 24)
mg/LTheranova 400Elisio-17H
Change From Baseline in Beta-2 Microglobulin (mg/L) at End of Study (up to Week 24)-3.95 ± 5.614-1.16 ± 6.128
Statistical analysis
  • Theranova 400 vs Elisio-17H · ANCOVA · p = 0.1824 · Mean difference (final values): -1.17

Adverse events

Collected over AEs/SAEs were collected after the informed consent was signed and throughout the study (week 24), until the end of study visit (week 25-26).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Theranova 4003/86 (3.5%)15/86 (17.4%)14/86 (16.3%)
Elisio-17H3/85 (3.5%)23/85 (27.1%)11/85 (12.9%)
Most frequent serious events
Showing 10 of 46
Most frequent serious events
EventTheranova 400Elisio-17H
FLUID OVERLOADMetabolism and nutrition disorders1/863/85
ACUTE MYOCARDIAL INFARCTIONCardiac disorders1/862/85
NON-CARDIAC CHEST PAINGeneral disorders0/862/85
ACUTE RESPIRATORY FAILURERespiratory, thoracic and mediastinal disorders0/862/85
PYREXIAGeneral disorders2/860/85
PNEUMONIAInfections and infestations2/861/85
ANGINA PECTORISCardiac disorders0/861/85
ATRIAL FIBRILLATIONCardiac disorders0/861/85
BRADYCARDIACardiac disorders0/861/85
CARDIAC ARRESTCardiac disorders1/861/85
Most frequent other events
Most frequent other events
EventTheranova 400Elisio-17H
PROCEDURAL HYPOTENSIONInjury, poisoning and procedural complications3/867/85
NAUSEAGastrointestinal disorders6/861/85
COUGHRespiratory, thoracic and mediastinal disorders6/863/85

Baseline characteristics

Age, Continuous
Age, Continuous(years)Theranova 400Elisio-17HTotal
Mean58.5 ± 13.5259.7 ± 12.459.1 ± 12.95
Sex: Female, Male
Sex: Female, Male(Participants)Theranova 400Elisio-17HTotal
Female323567
Male5451105
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Theranova 400Elisio-17HTotal
American Indian or Alaska Native000
Asian527
Black or African American333568
Native Hawaiian or Other Pacific Islander336
White404282
Other549
Region of Enrollment
Region of Enrollment(Participants)Theranova 400Elisio-17HTotal
United States8686172
08

Study locations

20 sites
  • DaVita Corona
    Corona, California 92881, United States
  • DaVita Riverside
    Riverside, California 92501, United States
  • DaVita Inc, Greater Hartford Nephrology
    Bloomfield, Connecticut 06002, United States
  • DaVita Inc., Waterbury Dialysis
    Middlebury, Connecticut 06762, United States
  • Dialysis Center, Inc. Albany
    Albany, Georgia 31701, United States
  • Dialysis Center, Inc. Boston
    Boston, Massachusetts 02111, United States
  • Dialysis Center, Inc. Kidney Associates of Kansas City
    Belton, Missouri 64012, United States
  • Dialysis Center of Lincoln
    Lincoln, Nebraska 68510, United States
  • DaVita Five Star Dialysis Center
    Las Vegas, Nevada 89128, United States
  • DaVita Inc., South Las Vegas Dialysis
    Las Vegas, Nevada 89169, United States
  • Dialysis Center, Inc. North Brunswick
    North Brunswick, New Jersey 08902, United States
  • DaVita Inc., Bronx Dialysis Center
    The Bronx, New York 10461, United States
  • Dialysis Center, Inc. Philidelphia
    Philadelphia, Pennsylvania 19129, United States
  • Dialysis Center, Inc. Holston River Clinic
    Knoxville, Tennessee 37924, United States
  • DaVita Inc., Transmountain Dialysis
    El Paso, Texas 79902, United States
  • DaVita Inc., Medical Center Dialysis
    Houston, Texas 77004, United States
  • DaVita Renal Center of Lewisville
    Lewisville, Texas 75057, United States
  • DaVita Inc., Northwest Medical Center Dialysis
    San Antonio, Texas 78229, United States
  • DaVita Floyd Curl Dialysis
    San Antonio, Texas 78240, United States
  • DaVita Inc., Norfolk Dialysis
    Chesapeake, Virginia 23320, United States
09

References and documents

Publications

  • Weiner DE, Falzon L, Skoufos L, Bernardo A, Beck W, Xiao M, Tran H. Efficacy and Safety of Expanded Hemodialysis with the Theranova 400 Dialyzer: A Randomized Controlled Trial. Clin J Am Soc Nephrol. 2020 Sep 7;15(9):1310-1319. doi: 10.2215/CJN.01210120. Epub 2020 Aug 25. PubMed 32843372 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2017 to primary completion in Oct 2018, 12 months.

Results were first posted in Dec 2020, 2 years 1 month after primary completion. A results delay was requested in Nov 2018.

Of 78 industry-sponsored interventional studies with no phase under Kidney Failure, Chronic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 40. This study's 12 months is below that.

Counting every sponsor, half of 427 studies reached it within 22 months; a quarter within 8 and three quarters within 45.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2017
First posted
Aug 22, 2017
StartActual
Sep 29, 2017
Primary completionActual
Oct 27, 2018
CompletionActual
Oct 27, 2018
Results delay requested
Nov 9, 2018
Results first posted
Dec 19, 2020
Last update
Jul 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03257410
Lead sponsor
Vantive Health LLC
Responsible party
Sponsor
First posted
Aug 22, 2017
Start date
Sep 29, 2017
Primary completion
Oct 27, 2018
Completion
Oct 27, 2018
Results posted
Dec 19, 2020
Last update
Jul 14, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion